---
{"dg-publish":true,"permalink":"/usmle/reproductive/breast-cancer/","tags":["t1"]}
---

# Breast anatomy
---
![Pasted image 20241124144632.png](/img/user/appendix/Pasted%20image%2020241124144632.png)
- Terminal ductal lobular units (TDLU)
	- Basic histopathological units of the mammary gland 
	- Consist of:
		- Lobule of the mammary gland: (functional unit of the breast) 
			- Intralobular stroma: loose, cell-rich connective tissue
			- <span style="background:rgba(240, 200, 0, 0.2)">Intralobular terminal (milk) duct with multiple outpouchings called acini or ductules (site of milk production)</span>
				- Structure: tubulo-alveolar with two-layered glandular epithelium 
					- <span style="background:rgba(240, 200, 0, 0.2)">Outer layer: myoepithelial cells (contractile</span>, route the milk to the ducts in lactating breasts)
					- <span style="background:rgba(240, 200, 0, 0.2)">Inner layer</span>: cubic, apocrine glandular epithelial cells (<span style="background:rgba(240, 200, 0, 0.2)">can produce milk</span>)
		- Extralobular terminal duct

![Pasted image 20241018091605.png](/img/user/appendix/Pasted%20image%2020241018091605.png)

# Overview
---
**I. Benign Breast Diseases**
- **Fibrocystic Changes:**
    - **General:** Premenopausal; bilateral, often painful, lumpy breasts, symptoms vary with menstrual cycle. Cysts may have a "blue dome" appearance.
    - **Nonproliferative lesions:** No increased cancer risk.
    - **Sclerosing Adenosis:** Proliferative; acini, stromal fibrosis, often calcifications (can mimic cancer). Slight �?cancer risk.
    - **Epithelial Hyperplasia (with atypia - ADH, ALH):** Proliferative; significantly �?cancer risk (4-5x).
- **Inflammatory Processes:**
    - **Fat Necrosis:** History of trauma/surgery; firm mass, mammographic calcifications (oil cyst), or skin changes mimicking cancer. Biopsy: necrotic fat, lipid-laden macrophages, giant cells.
    - **Lactational Mastitis:** [[USMLE/Reproductive/Infant nutrition and breastfeeding\|Breastfeeding]] woman; localized erythema, pain, fever. Usually _S. aureus_. **Key:** Continue [[USMLE/Reproductive/Infant nutrition and breastfeeding\|breastfeeding]]/pumping + [[USMLE/Pharmacology/Antibiotics\|antibiotics]].
    - **[[USMLE/Reproductive/Mammary duct ectasia\|Mammary Duct Ectasia]]:** Perimenopausal women, smokers common; periareolar mass, nipple retraction, thick, multicolored (often green-brown) [[USMLE/Reproductive/Nipple discharge\|nipple discharge]]. Plasma cells on histology.
- **Benign Tumors:**
    - **Fibroadenoma:** Most common in women < 35 yrs; well-defined, mobile ("breast mouse"), rubbery, painless mass. Estrogen sensitive. Usually no increased cancer risk.
    - <span style="background:rgba(240, 200, 0, 0.2)">**Intraductal Papilloma:** Most common cause of bloody or serosanguineous nipple discharge. Small tumor in lactiferous duct. Slight �?cancer risk.</span>
    - **Phyllodes Tumor:** Large, bulky mass with "leaf-like" projections on histology. More common in 5th decade. Can be benign, borderline, or malignant.
- **Gynecomastia:** Benign male breast enlargement due to �?estrogen relative to androgens. Causes: physiologic (newborn, puberty, elderly), cirrhosis, testicular tumors, Klinefelter syndrome, drugs (e.g., **S**pironolactone, **K**etoconazole, **C**imetidine).
    

**II. Malignant Breast Diseases (Breast Cancer)**

- **Key Risk Factors:** �?Age, BRCA1/BRCA2, family history, atypical hyperplasia, unopposed estrogen exposure.
- **Noninvasive Carcinomas:**
    - **Ductal Carcinoma In Situ (DCIS):** Malignant cells in duct _without_ basement membrane invasion. Often seen as microcalcifications on mammography. Precursor to invasive ductal carcinoma.
    - **Lobular Carcinoma In Situ (LCIS):** Abnormal cells in lobules _without_ basement membrane invasion. _Loss of E-cadherin_ is characteristic. Often incidental finding. Increased risk of invasive cancer in _either_ breast.
    - **Paget Disease of the Nipple:** Eczematous, crusted lesion of nipple/areola. Due to intraepithelial spread of adenocarcinoma cells (Paget cells) from underlying DCIS or invasive cancer.
- **Invasive Carcinomas:**
    - **Invasive Ductal Carcinoma (IDC), No Special Type (NST):** Most common type. Firm, "rock-hard" mass with irregular borders, gritty texture. Small, glandular, ductlike cells in desmoplastic stroma.
    - **Invasive Lobular Carcinoma (ILC):** _Loss of E-cadherin_ leads to cells infiltrating in a single-file ("<span style="background:rgba(240, 200, 0, 0.2)">Indian file</span>") pattern. Often multifocal and bilateral. May present as subtle thickening rather than a discrete mass.
    - **Inflammatory Breast Cancer (IBC):** Aggressive. Diffuse breast erythema, warmth, swelling, and _peau d'orange_ (orange peel skin) due to dermal lymphatic invasion. Often lacks a palpable mass. Poor prognosis.

>[!tip] 
><span style="background:rgba(240, 200, 0, 0.2)">Nipple discharge happens in duct-related diseases, or diseases affecting the nipple skin. </span>
><span style="background:rgba(240, 200, 0, 0.2)">It doesn't happen in lobule-related diseases, or stromal cancer.</span>

# Benign cancer
---
## [[USMLE/Reproductive/Intraductal papilloma\|Intraductal papilloma]]
- <span style="background:rgba(240, 200, 0, 0.2)">BIoody [[USMLE/Reproductive/Nipple discharge\|nipple discharge]] in pre-menopausal women (vs. Papillary Carcinoma)</span>
- <span style="background:rgba(240, 200, 0, 0.2)">FibrovascuIar projections lined by luminal myoepithelial cells (vs. Papillary Carcinoma)</span>

![Pasted image 20241017174131.png](/img/user/appendix/Pasted%20image%2020241017174131.png)
![Pasted image 20241017174211.png](/img/user/appendix/Pasted%20image%2020241017174211.png)

>[!Mnemonic] 
>- <font color="#ffc000">I</font>ntraductal = Myoepithelium <font color="#ffc000">I</font>ncluded
>- <font color="#ffc000">P</font>apillary = Myoepithelium <font color="#ffc000">P</font>opped

## Fibroadenoma
- Refers to a marble-like, rubbery mobile, stromal/glandular benign tumor
- <span style="background:rgba(240, 200, 0, 0.2)">Estrogen sensitive (will enlarge during pregnancy/menstrual cycle)</span>
- Typically occurs in 15-35 y/o women
- Biopsy: fibrous and glandular tissue![Pasted image 20241018090342.png](/img/user/appendix/Pasted%20image%2020241018090342.png)

>[!Mnemonic] 
>fib<font color="#ffc000">RO</font>adenoma = est<font color="#ffc000">RO</font>gen sensitive

## Phyllodes tumor
- Refers to a fibroepithelial tumor that ranges from benign (mostly) to malignant (rarely)
- <span style="background:rgba(240, 200, 0, 0.2)">Characteristic **leaf-like projections into epithelium-lined stroma & dilated lumen**</span>![Pasted image 20250218094538.png](/img/user/appendix/Pasted%20image%2020250218094538.png)
- Typically occurs in **40-50 y/o women**

| Feature         | Fibroadenoma                                                                                        | Phyllodes Tumor                                                                                                                                                                    |
| --------------- | --------------------------------------------------------------------------------------------------- | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |
| **Typical Age** | Younger (15-35 yrs)                                                                                 | Older (40-50 yrs)                                                                                                                                                                  |
| **Prevalence**  | <span style="background:rgba(240, 200, 0, 0.2)">Very common</span>, most common benign breast tumor | <span style="background:rgba(240, 200, 0, 0.2)">Rare</span>, <1%                                                                                                                   |
| **Growth**      | Slow, often hormone-sensitive                                                                       | Can be **rapid**                                                                                                                                                                   |
| **Size**        | Usually <3 cm                                                                                       | <span style="background:rgba(240, 200, 0, 0.2)">Often **larger**</span>                                                                                                            |
| **Histology**   | **Benign stroma** & epithelium, well-circumscribed                                                  | <span style="background:rgba(240, 200, 0, 0.2)">**Increased STROMAL CELLULARITY**, atypia, mitoses define grade (Benign, Borderline, Malignant). **LEAF-LIKE** projections.</span> |
| **Behavior**    | Benign                                                                                              | Can be benign, borderline, or **malignant** (hematogenous spread)                                                                                                                  |
| **Recurrence**  | Rare after excision                                                                                 | Higher risk, especially if margins inadequate or higher grade                                                                                                                      |
| **Management**  | Observation or simple excision                                                                      | <span style="background:rgba(240, 200, 0, 0.2)">**WIDE LOCAL EXCISION** (with clear margins) is crucial for all types.</span>                                                      |
# Malignant cancer
---
![Pasted image 20240416200003.png](/img/user/appendix/Pasted%20image%2020240416200003.png)
## Noninvasive carcinomas
### Ductal carcinoma in situ (DCIS)
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">No penetration of the basement membrane</span>
	- Preceded by ductal atypia
	- Frequently appears as a pattern of grouped <span style="background:rgba(240, 200, 0, 0.2)">microcalcifications</span> on mammography
		- <span style="background:rgba(240, 200, 0, 0.2)">Abnormal cell growth and death will leave calcium deposits</span>
		- Because DCIS often doesn't cause noticeable symptoms like a lump, these microcalcifications serve as an important visual indicator.
	- Higher risk of subsequent ipsilateral invasive carcinoma
- Comedocarcinoma
	- Characteristics: subtype of DCIS characterized by central necrosis![L67791.jpg](/img/user/appendix/L67791.jpg)

>[!tip] 
>Noninvasive carcinomas are characterized by the absence of stromal invasion.
### Lobular carcinoma in situ (LCIS)
- Refers to proliferation of lobular cells but has not yet invaded basement membrane
- <span style="background:rgba(240, 200, 0, 0.2)">Lacks E-Cadherin</span>

>[!Mnemonic] 
><font color="#ffc000">L</font>obular <font color="#ffc000">C</font>arcinoma <font color="#ffc000">L</font>acks <font color="#ffc000">C</font>adherin
## Invasive carcinomas
### Invasive ductal carcinoma (IDC)
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">Most common type of invasive breast cancer (�?80%) </span>
	- Aggressive formation of metastases
- Localization
	- Unilateral
	- Mostly unifocal
#### Medullary breast cancer 
- Characteristics
	- Rare subtype of invasive ductal carcinoma
	- Most common tumor associated with the BRCA1 mutation
	- Well-circumscribed soft tumor with smooth borders (may appear benign)![L67792.jpg](/img/user/appendix/L67792.jpg)
	- Usually triple-negative
	- Lymphadenopathy 
- Differential diagnosis: fibroadenoma
### Invasive lobular carcinoma (ILC) 
- Characteristics
	- <span style="background:rgba(240, 200, 0, 0.2)">�?10% of all invasive breast carcinomas</span>
	- Less aggressive than ductal carcinoma
	- Monomorphic cells in a <span style="background:rgba(240, 200, 0, 0.2)">single file pattern</span> due to a decrease in E-cadherin expression![paste-225636106895941.jpg](/img/user/appendix/paste-225636106895941.jpg)
- Localization
	- <span style="background:rgba(240, 200, 0, 0.2)">Bilateral</span> in �?20% of cases
	- <span style="background:rgba(240, 200, 0, 0.2)">Frequently multifocal</span>

>[!Mnemonic] 
><font color="#ffc000">ILC</font> = <font color="#ffc000">I</font>ndividual <font color="#ffc000">L</font>ine <font color="#ffc000">C</font>arcinoma
# Clinical features
---
## Locally advanced disease
- Skin
	- <span style="background:rgba(240, 200, 0, 0.2)">Retractions or dimpling</span> (due to fixation to the pectoral muscles, deep fascia, Cooper ligaments, and/or overlying skin)
	- Peau d'orange (see below)
# Subtypes and variants
---
## Inflammatory conditions (DDx)
- Mastitis
- [[USMLE/Reproductive/Mammary duct ectasia\|Mammary duct ectasia]]
- [[USMLE/Reproductive/Fat necrosis of the breast\|Fat necrosis of the breast]]
## Paget disease of the breast
- Definition: a rare type of breast cancer that <span style="background:rgba(240, 200, 0, 0.2)">affects the lactiferous ducts and the skin of the nipple and areola</span>
- Pathogenesis: migratory/epidermotropic theory: <span style="background:rgba(240, 200, 0, 0.2)">neoplastic ductal epithelial cells from an underlying DCIS or IDC  move through the lactiferous ducts and invade the surrounding epidermis of the nipple.</span>
- Clinical features![Pasted image 20240412145835.png](/img/user/appendix/Pasted%20image%2020240412145835.png)
	- <span style="background:rgba(240, 200, 0, 0.2)">Erythematous, scaly, or vesicular rash affecting the nipple and areola</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Pruritus; burning sensation</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Nipple retraction</span>
	- Ulceration that causes blood-tinged [[USMLE/Reproductive/Nipple discharge\|nipple discharge]]
- Diagnostics
	- Punch/wedge or surface biopsy of nipple tissue: <span style="background:rgba(240, 200, 0, 0.2)">Paget cells</span> confirm disease.![Pasted image 20241010083736.png](/img/user/appendix/Pasted%20image%2020241010083736.png)
## Inflammatory breast cancer (IBC)
- Definition: a rare form of advanced, aggressive invasive carcinoma <span style="background:rgba(240, 200, 0, 0.2)">characterized by dermal lymphatic invasion of tumor cells</span>
- Clinical features![Pasted image 20240416202309.png](/img/user/appendix/Pasted%20image%2020240416202309.png)
	- Peau d'orange
		- <span style="background:rgba(240, 200, 0, 0.2)">Erythematous, warm, and edematous skin plaques with prominent hair follicles that resemble orange peel</span>
		- Caused by <span style="background:rgba(240, 200, 0, 0.2)">obstruction of the lymphatic channels</span> due to tumor growth  
	- <span style="background:rgba(240, 200, 0, 0.2)">Tenderness</span>, burning sensation
	- Blood-tinged [[USMLE/Reproductive/Nipple discharge\|nipple discharge]]
	- <span style="background:rgba(240, 200, 0, 0.2)">Signs of metastatic disease (e.g., axillary lymphadenopathy)</span> 
	- <span style="background:rgba(240, 200, 0, 0.2)">Usually no palpable mass</span>
- Differential diagnosis
	- <span style="background:rgba(240, 200, 0, 0.2)">Mastitis</span>
		- Fever
		- No Peau d'orange
		- Good response to [[USMLE/Pharmacology/Antibiotics\|antibiotics]]
	- Paget disease of the breast
	- Breast abscess

>[!tip] 
>It is called inflammatory breast cancer because its appearance resembles inflammation, but there is actually no inflammation!
# Diagnostics
---
## Receptor testing
![Pasted image 20240311145001.png](/img/user/appendix/Pasted%20image%2020240311145001.png)
- Hormone receptors (HR) positive
	- [[USMLE/Reproductive/Androgen and estrogen synthesis\|Estrogen]] receptor
	- Progestogen receptor
- Human epidermal growth factor receptor 2 (HER2/neu, c-erbB2) positive
- Triple negative
- Ranking
	- <span style="background:rgba(240, 200, 0, 0.2)">Aggressive: TN > HER2+ > HR+</span>
	- <span style="background:rgba(240, 200, 0, 0.2)">Prognosis: HR+/HER2- > HR+/HER2+ > HR-/HER2+ > TN</span>
# Treatment
---
## Systemic therapy
### ERBB2-targeted therapy <span style="background:rgba(240, 200, 0, 0.2)">(ERBB2 = HER2)</span>
ERBB2-targeted therapy includes <span style="background:rgba(240, 200, 0, 0.2)">ERBB2 antibodies (e.g., trastuzumab, pertuzumab) and tyrosine kinase inhibitors (e.g., lapatinib, neratinib).</span>
- Indication: all ERBB2+ tumors
- First-line agent: trastuzumab
	- A humanized monoclonal antibody against the ERBB2 tyrosine kinase receptor; used in the treatment of ERBB2+ breast and [[USMLE/GI/Gastric cancer\|gastric cancer]] 
	- <span style="background:rgba(240, 200, 0, 0.2)">Mechanism of action: targets c-erbB2 tyrosine kinase receptor �?�?of ERBB2-initiated cellular signaling and �?antibody-dependent cytotoxicity �?�?tumor growth</span>
	- Adverse effects: cardiotoxicity (e.g., [[USMLE/Cardiology/Dilated cardiomyopathy\|dilated cardiomyopathy]] with systolic CHF)

